We have located links that may give you full text access.
The use of LP533401 as a therapeutic option for renal osteodystrophy affects, renal calcium handling, vitamin D metabolism and bone health in uremic rats.
Expert Opinion on Therapeutic Targets 2019 Februrary 26
BACKGROUND: Klotho is a key regulator of phosphate and Ca2+ - transport in the kidney. Recently, we showed that treatment with LP533401 improved bone health in rats with chronic kidney disease (CKD) via the normalization of serum phosphate resulting from the reduced renal expression of phosphate co-transporters, including Klotho.
METHODS: We evaluated the effect of LP533401 therapy on Klotho-expression dependent Ca2+ - transporters, renal calcium handling and the potential consequences for the bone of uremic rats.
RESULTS: Treatment with LP533401 and its vehicle, resulted in the inhibition of transient receptor potential vanilloid receptor subtypes 5 and 6 (TRPV5, TRPV6) and calbidin (CaBP-28k, CaBP-9k) expression. The compensatory acceleration in renal expression of Na+/Ca2+ -exchanger (NCX1), 25-hydroxyvitamin D-1α-hydroxylase (CYP27B1), the intensification of vitamin D metabolism and disruption of sophisticated balance between 1,25-dihydroxyvitamin D - serotonin was observed, especially in rats treated with LP533401. The imbalance between 1,25-dihydroxyvitamin D - serotonin levels led to intensified bone remodeling and improvement in bone geometry, mineral status and strength in animals treated with LP533401.
CONCLUSION: The modulation of circulating serotonin and its relation to other regulators of calcium handling can play an important role in calcium homeostasis and bone integrity in CKD rats treated with LP533401.
METHODS: We evaluated the effect of LP533401 therapy on Klotho-expression dependent Ca2+ - transporters, renal calcium handling and the potential consequences for the bone of uremic rats.
RESULTS: Treatment with LP533401 and its vehicle, resulted in the inhibition of transient receptor potential vanilloid receptor subtypes 5 and 6 (TRPV5, TRPV6) and calbidin (CaBP-28k, CaBP-9k) expression. The compensatory acceleration in renal expression of Na+/Ca2+ -exchanger (NCX1), 25-hydroxyvitamin D-1α-hydroxylase (CYP27B1), the intensification of vitamin D metabolism and disruption of sophisticated balance between 1,25-dihydroxyvitamin D - serotonin was observed, especially in rats treated with LP533401. The imbalance between 1,25-dihydroxyvitamin D - serotonin levels led to intensified bone remodeling and improvement in bone geometry, mineral status and strength in animals treated with LP533401.
CONCLUSION: The modulation of circulating serotonin and its relation to other regulators of calcium handling can play an important role in calcium homeostasis and bone integrity in CKD rats treated with LP533401.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app